| alendronate / Generic mfg. |
ChiCTR-TNRC-09000478: The Role of Alendronate in Preventing New Vertebral Compression Fractures In Severe Osteoporotic Patients After Percutaneous Vertebral Augmentation: A Perspective Cohort Study |
|
|
| Completed | 4 | 80 | | Alendronate 70mg orally taken once a week+Cacium and vitamin D supplement ;Cacium and vitamin D supplement | West China Hospital, Sichuan University; Level of the institution：, Self-funding | Osteoporosis | | | | |
EASTIRA, ChiCTR-TRC-09000473: Efficacy and safety of Alendronate on Structural Benefit and Inflammation in Rheumatoid Arthritis(RA): A randomized, open, placebo-controlled, multicentre clinical trial. |
|
|
| Completed | 4 | 320 | | MTX 7.5-20mg, orally taken once weekly for 48 week ;MTX7.5-20mg, orally taken once weekly combined Alendronate Sodium 70mg,orally taken once weekly for 48 weeks | People's Hospital, Peking University; Ministry of Science and Technology of China, National Key Technologies R&D Program | Rheumatoid Arthritis | | | | |
ChiCTR-OCH-11001837: The clinical study on the effects of bone metabolism in diabetic nephropathy treated by alendronate |
|
|
| Completed | 4 | 60 | | Alendronate+Calcium Carbonate and Vitamin D3 Table ;Alendronate+Calcium Carbonate and Vitamin D3 Table ;Alendronate+Calcium Carbonate and Vitamin D3 Table | Department of Endocrine, Zhujiang Hospital; Level of the institution：, Guangdong Pharmeceutical Association | diabetic nephropathy, bone metabolism | | | | |
2013-001222-26: Markers of bone in diabetics and the effect of bone treatment. Markører for knoglestatus hos diabetikere og effekten af knoglebehandling. |
|
|
| Ongoing | 4 | 64 | Europe | Alendronat, Capsule, Alendronat Arrow (in the study the effect of Alendronate is examined and there may be switched between types) | Aalborg University Hospital, CARING (EU) | Diabetes Mellitus and Osteopenia/Osteoporosis Diabetes Mellitus and Osteopeni/Osteoporose, Diabetes and bone fragility Sukkersyge og knogleskørhed, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR-TRC-11001818: Prevention and treatment of osteoporosis in organ transplant recipients: randomized open controlled clinical trial |
|
|
| Completed | 4 | 420 | | no ;Calcium Carbonate and Vitamin D3 Tablets ;Calcitriol ;Calcium Carbonate and Vitamin D3 Tablets, Calcitriol ;Calcium Carbonate and Vitamin D3 Tablets, Calcitriol ;Calcium Carbonate and Vitamin D3 Tablets, Calcitriol ;Calcium Carbonate and Vitamin D3 Tablets, Calcitriol, Alendronate | The General Hospital of Chinese People’s Armed Police Forces; The General Hospital of Chinese People’s Armed Police Forces, Self-financing | Organ transplant recipient, Osteoporosis | | | | |
2005-003924-21: A Randomised, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded versus Generic Alendronate Tablets |
|
|
| Ongoing | 4 | 25 | Europe | Fosamax Once Weekly 70 mg Tablets, Alendronic Acid 70 mg Tablets, Fosamax Once Weekly 70 mg Tablets, Alendronic Acid 70 mg Tablets | University of Nottingham | Osteoporosis | | | | |
2006-000900-17: A randomised double-blind placebo controlled trial of the oral bisphosphonate, Alendronate, plus intravenous pamidronate, in active diabetic Charcot neuroarthropathy (CN). |
|
|
| Ongoing | 4 | 78 | Europe | Fosamax® Once Weekly 70mg, Pamidronate, any, Not applicable, Fosamax, Pamidronate, Fosamax, Pamidronate | The University of Manchester, Central Manchester and Manchester Children\'s University NHS trust | Charcot neuroarthropathyCode: E10.6 Insulin + M14.6Code: E11.6 Insulin + M14.6 | | | | |
2009-015058-38: Improving the outcome for patients after osteoporotic femoral fractures |
|
|
| Ongoing | 4 | 120 | Europe | FOSAMAX, FORSTEO, ADCAL-D3, NDC 006-0031-44, EU/1/03/247/001, EU/1/03/247/002, ADCAL-D3, FOSAMAX, FORSTEO, ADCAL-D3, FOSAMAX, FORSTEO, ADCAL-D3 | University of Leeds | OSTEOPOROTIC FEMORAL FRACTURE | | | | |
2012-000321-41: Preventive treatment with alendronate for osteoporosis in people with spinal cord injuries Tratamiento preventivo con alendranato de la osteoporosis en los lesionados medulares |
|
|
| Ongoing | 4 | 66 | Europe | AC ALENDRONICO KERN PHARMA 70MG, 656456, AC ALENDRONICO SEMANAL 70MG, AC ALENDRONICO SEMANAL 70MG | FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACIÓN Y LA INTEGRACIÓN, MINISTERIO DE SANIDAD | Preventing loss of bone density in patients with spinal cord injury of traumatic etiology complete during the first year of evolution of the lesion. Prevención de la pérdida de la densidad de la masa ósea en pacientes con lesión de la médula espinal completa de etiologÃa traumática durante el primer año de evolución de la lesión. | | | | |
ChiCTR-OPC-16010120: The effect and mechanism of the synergistic effect of estradiol and testosterone in postmenopausal osteoporosis |
|
|
| Recruiting | 4 | 600 | | calcium carbonate ;calcium carbonate and Calcitriol ;alendronate，calcium carbonate and Calcitriol | Liaocheng people's hospital; Liaocheng People's Hospital, Natural Science Foundation of Shandong province (No. ZR2016HP11) | primary osteoporosis | | | | |
ChiCTR-IPR-16009416: Concise, accurate diagnosis and treatment eveluation of osteoporosis patients using new imaging techniques |
|
|
| Not yet recruiting | 4 | 80 | | Oral take calcium tablet (≥1000mg) and Vitamin D (≥400IU) daily ;Oral take Alendronate Sodium and Vitamin D3 Tablets (1 tablet / day, 70mg/2800IU per tablet) | Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Shanghai Shen Kang Hospital Development Center | Osteoporosis | | | | |
| Ongoing | 4 | 376 | Europe | Teriparatide biosimilar, Alendronic acid, Solution for injection, Tablet | Gedeon Richter Ibérica, Gedeon Richter Ibérica | Osteoporosis in postmenopausal women at increased risk of fracture. Osteoporosis en mujeres postmenopausicas con riesgo de fractura, Menopausal women with lower bone density and risk of fracture Mujeres menopáusicas con baja densidad ósea y riesgo de fractura, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
2020-005040-35: The effect of effervescent alendronate on bone turnover Effekten af Binosto® på knogleomsætningen |
|
|
| Not yet recruiting | 4 | 64 | Europe | Effervescent tablet, Tablet, Binosto, Fosamax | Aarhus University Hospital, PharmaPrim | Osteopenia, i.e. bone mineral density T-score < -1, Low bone mass, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
NCT05325515: The Effect of Effervescent Alendronate on Bone Turnover |
|
|
| Completed | 4 | 64 | Europe | Conventional alendronate, Effervescent and buffered alendronate | Aarhus University Hospital | Osteopenia or Osteoporosis | 09/22 | 12/22 | | |
ChiCTR2100044765: The efficacy of Aendronate Sodium and Vitamin D3 tablets (Gubangjia) in the treatment of early osteonecrosis of the femoral head with osteoporosis |
|
|
| Recruiting | 4 | 40 | | Alendronate and Vitamin D3 Tablets (GuBangjia) (70 mg ALN + 2800 IU Vitamin D3/tablet) once a week, one pill for each time, with an interval of at least 3 days between doses, for 12 months Combined with conventional treatment regimen (Protective weight-bearing, drug therapy, traditional Chinese medicine therapy ;Placebo once a week, one pill for each time, with an interval of at least 3 days between doses, combined with conventional treatment regimen for 12 months | Chinese PLA General Hospital; Chinese PLA General Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Early osteonecrosis of the femoral head with osteoporosis | | | | |
NCT03623633: Comparative Antiresorptive Efficacy Discontinuation of Denosumab |
|
|
| Active, not recruiting | 4 | 51 | US | denosumab, Prolia, alendronate, Fosamax, raloxifene, Evista | Massachusetts General Hospital | Osteoporosis, Postmenopausal, Osteoporosis | 02/23 | 08/23 | | |
NCT05387200: Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis |
|
|
| Recruiting | 4 | 170 | RoW | Masibone S, Fosamax | Yonsei University | Osteoporosis | 05/23 | 05/23 | | |
NCT04739592: A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis |
|
|
| Recruiting | 4 | 60 | RoW | alendronate sodium vitamin D3 tablets, Placebo | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Knee Osteoarthritis | 07/23 | 07/24 | | |
NCT05527548: A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR |
|
|
| Recruiting | 4 | 64 | RoW | Alendronate (ALN) | Chinese University of Hong Kong | ACL Reconstruction | 10/25 | 12/25 | | |
NCT05645289: Efficacy and Safety of Minodronate in Patients With Low Back Pain |
|
|
| Not yet recruiting | 4 | 72 | RoW | Minodronate, Difumi, Alendronate, Fushanmei | Peking University Third Hospital | Postmenopausal Osteoporosis | 12/23 | 04/24 | | |
NCT04177940: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study |
|
|
| Active, not recruiting | 4 | 45 | US | DMAB Discontinuation and Switching | University of Alabama at Birmingham, Maastricht University, Vrije Universiteit Brussel, Amgen | Osteoporosis | 12/24 | 08/25 | | |
NCT06264609: Precision Medicine Approach for Osteoporosis - Follow Up Study |
|
|
| Enrolling by invitation | 4 | 40 | US | Alendronate, Teriparatide | Hartmut Malluche, MD | Osteoporosis | 12/29 | 12/29 | | |
ChiCTR2100045485: Comparative study of zoledronic acid and alendronate in the treatment of postmenopausal osteoporosis |
|
|
| Recruiting | 4 | 400 | | Alendronate 70mg/week orally ;Zoledronic acid 5mg/year intravenously | The First Affiliated Hospital of Xi 'an Jiaotong University; The First Affiliated Hospital of Xi 'an Jiaotong University, Academic community support | Postmenopausal osteoporosis | | | | |
| Recruiting | 4 | 70 | Europe | Denosumab, Prolia, Alendronate Sodium, Fosamax | Aristotle University Of Thessaloniki, 424 General Military Hospital | Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal | 12/24 | 12/25 | | |
ChiCTR2300070789: Effect of Denosumab on Glucose Metabolism in Postmenopausal Osteoporotic Women with Prediabetes: A Study Protocol for a 12-month Multicenter, Randomized, Open-label, Controlled Trial |
|
|
| Not yet recruiting | 4 | 212 | | Denosumab ;Alendronate | Chinese PLA General Hospital; Chinese People’s Liberation Army General Hospital, the Excellent Young Scholars Training Program (2020-YQPY-001)；Young Elite Scientist Sponsorship Program (BYESS2022); National Natural Science Foundation of China (81972102). | prediabetes；osteoporosis | | | | |
| Recruiting | 4 | 200 | | Alendronate sodium treatment was 70mg/ time, once a week oral. Zoledronic acid was given 5mg/ time intravenously, only once in 12 months; Desomumab, 60mg/ time, subcutaneous injection every 6 months in the abdomen.; Alendronate sodium treatment was 70mg/ time, once a week oral. Zoledronic acid was given 5mg/ time intravenously, only once in 12 months; Desomumab, 60mg/ time, subcutaneous injection every 6 months in the abdomen. | Tongji Hospital, Tongji University School of Medicine; Tongji Hospital, Tongji University School of Medicine, Self-raised funds | Type 2 diabetes mellitus and osteoprosis | | | | |
NCT05091099: The Optimal Sequential Therapy After Long Term Denosumab Treatment |
|
|
| Recruiting | 4 | 44 | RoW | Alendronate, Zoledronic acid | National Taiwan University Hospital | Osteoporosis | 12/25 | 12/25 | | |
ChiCTR2300067942: Prospective Precision Intervention Study for Osteoporotic Fractures Based on Risk Stratification |
|
|
| Not yet recruiting | 4 | 15000 | | Active health/bone health basic supplements (calcium and vitamin D)/TCM treatment ;Oral alendronate therapy/oral risephosphate therapy/denosumab therapy/intravenous bisphosphonate therapy ;Teriparatide sequential oral alendronate sodium treatment/teriparatide sequential oral risephosphate sodium treatment/teriparatide sequential oral denosumab treatment/teriparatide sequential intravenous bisphosphonate treatment | The Second XiangYa Hospital, Central South University; The Second XiangYa Hospital, Central South University, National Key Research and Development Program (No.2021YFC2501705) | Osteoporotic fractures | | | | |
NCT05151484: Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover |
|
|
| Recruiting | 4 | 60 | US | Teriparatide, Alendronate | Hartmut Malluche, MD, National Institute on Aging (NIA) | Age-Related Osteoporosis | 08/26 | 08/26 | | |
ChiCTR1900022821: Multi-Center Prospective Study for Effect of Bisphosphonate in the Prevention and Treatment of Aseptic Loosening after Total Hip Arthroplasty |
|
|
| Recruiting | 4 | 702 | | Normal bone mass group 1 giving calcium carbonate D3 tablets (600 mg/day, oral), and alendronate sodium D3 tablets (1 tablet/week, oral) for 2 years versus Normal bone mass group 2: no intervention ;Osteoporosis group 1 giving Zoledronic acid: calcium carbonate D3 tablets (600 mg / day, oral), calcitriol capsules (0.25 ug / day, oral), zoledronic acid injection (5 mg intravenous drip, once a year) at least 3 year versus Osteoporosis group 2 giving Alendronate: calcium carbonate D3 tablets (600mg / day, | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Aseptic loosening of artificial joint | | | | |
| Active, not recruiting | 3 | 300 | | | Barwon Health, Astra Zeneca | Breast Cancer | | | | |
2006-005862-38: Prevention of Postmenopausal Bone Loss in Osteopenic Women with Alendronate given on a 70 mg Once-every two week Regimen : a 2-year, Double-blind, Placebo-controlled Clinical Trial |
|
|
| Ongoing | 3 | 150 | Europe | FOSAMAX, Fosamax, Alendronate, alendronate, Alendronate, alendronate | UCL Mont Godinne | osteopenia and postmenopausal patient | | | | |
2007-002744-22: Effet d\'un traitement anti-résorptif sur la perte osseuse chez le patient blessé médullaire |
|
|
| Ongoing | 3 | 56 | Europe | FOSAMAX, CALCIDOSE VITAMINE D, FOSAMAX, CALCIDOSE VITAMINE D, FOSAMAX, CALCIDOSE VITAMINE D | University Hospital of Montpellier | patient blessé medullaire | | | | |
2020-005343-23: Study of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metastatic hormonal receptor positive breast cancer. Studio del trattamento anti-riassorbimento con alendronato rispetto a nessun trattamento dopo l’interruzione della terapia con denosumab e inibitori dell’aromatasi in donne a basso rischio di frattura osteopeniche in post-menopausa affette da carcinoma mammario non metastatico positivo al recettore ormonale. |
|
|
| Not yet recruiting | 3 | 190 | Europe | Acido Alendronico, [Binosto], Effervescent tablet, BINOSTO - 70 MG COMPRESSE EFFERVESCENTI | IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A, Amgen, Abiogen Pharma S.p.A. | post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. osteoporosi post-menopausale in donne affette da carcinoma mammario non metastatico positivo per il recettore ormonale (HR+)., post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer. osteoporosi post-menopausale in donne affette da carcinoma mammario non metastatico positivo per il recettore ormonale (HR+), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT05305183: A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis |
|
|
| Not yet recruiting | 3 | 330 | RoW | Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo | Shandong New Time Pharmaceutical Co., LTD | Osteoporosis | 05/23 | 05/24 | | |
ChiCTR2200057843: Phase III, multicenter, randomized, open, positive-drug parallel control trial evaluating the efficacy and safety of injectable recombinant human parathyroid hormone (1-34) [56.5 μg] (SAL056) in postmenopausal women with osteoporosis at high risk of fracture |
|
|
| Recruiting | 3 | 448 | | SAL056: One (56.5μg) was dissolved in 1mL water for injection, and injected subcutaneously, once a week, into the thigh or abdominal wall. D calcium chewable tablets (Diqiao): oral, chewed and swallowed, 2 tablets a time, once a day. ;Alendronate sodium (fosamax) : fasting oral, 1 tablet, once a week; How to take the medicine: take it with a cup of water (about 250mL) after morning, fast within 30 minutes and keep standing or sitting up straight; D calcium chewable tablets (Diqiao) : oral, chewed and swallowed, 2 tablets& | Shanghai Sixth People's Hospital; Xinlitai (Suzhou) Pharmaceutical Co., LTD, Xinlitai (Suzhou) Pharmaceutical Co., LTD | Osteoporosis in postmenopausal women | | | | |
NCT04779216: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa |
|
|
| Active, not recruiting | 3 | 30 | US | Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab | Karen Klahr Miller, MD, Amgen | Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders | 09/24 | 09/25 | | |
| Recruiting | 3 | 700 | US | Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo | Wake Forest University Health Sciences, National Institute on Aging (NIA) | Bone Loss | 04/27 | 04/27 | | |
NCT04704947: Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis |
|
|
| Recruiting | 3 | 50 | RoW | nonselective beta blocker, Inderal, cardio-selective beta blocker group, concor, alendronate sodium, alendronate | Sherief Abd-Elsalam | Beta Blocker Toxicity | 10/30 | 10/30 | | |
2006-000635-94: A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or placebo in postmenopausal women with osteoporosis. |
|
|
| Ongoing | 2 | 50 | Europe | SB-462795 tablets, Overencapsulated Fosamax Tablets, SB-462795, Overencapsulated Fosamax Tablets, | GlaxoSmithKline Research & Development | Osteoporosis | | | | |
| Ongoing | 2 | 57 | Europe | Mono Sodium Olpadronate, IG-8801, | Gador S.A., Gador S.A. | non-specific Chronic Low Back Pain persisting for at least 3 months | | | | |
2015-005688-18: En randomiseret kontrolleret undersøgelse af alendronat som forebyggende behandling mod udvikling af glucocorticoid induceret osteoporose hos patienter der behandles for malignt lymfom. |
|
|
| Ongoing | 2 | 60 | Europe | alendronat, Tablet | Department of Hematology, Aalborg University Hospital, Department of Hematology | Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years Alder ≥ 18 år. Patienter der er nydiagnosticeret- eller har recidiv af malignt lymfom (lymfeknudekræft) uanset undertype og som forventes at skulle behandles med et af de anførte kemoterapiregimer. Forventet livslængde ≥2 år, Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years Alder ≥ 18 år. Patienter der er nydiagnosticeret- eller har recidiv af lymfeknudekræft, som forventes at skulle behandles med et af de anførte kemoterapiregimer. Forventet livslængde ≥2 år, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 69 | Europe | Placebo, Alendronate, Calcium, Vitamin D | University of Aarhus | Rheumatoid Arthritis, Osteoporosis | 12/21 | 12/21 | | |
2019-003570-11: The use of alendronate (Steovess) after denosumab discontinuation to prevent increase in bone turnover Het gebruik van alendronaat (Steovess) na stopzetting van denosumab om verhoogde botombouw te voorkomen. |
|
|
| Not yet recruiting | 2 | 40 | Europe | Effervescent tablet, Steovess | Ghent University Hospital, EffRx Pharmaceuticals SA, Amgen | erosive osteoarthritis of the interphalangeal finger joints, Arthrosis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT05397938: Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis |
|
|
| Not yet recruiting | 2 | 231 | RoW | JMT103, Alendronate sodium, JMT103 placebo, Alendronate sodium placebo | Shanghai JMT-Bio Inc. | Glucocorticoid Induced Osteoporosis | 07/22 | 06/23 | | |
NCT03396315: Bisphosphonates for Prevention of Post-Denosumab Bone Loss |
|
|
| Completed | 2 | 24 | US | Alendronate, fosamax, Zoledronic Acid, Reclast | Columbia University, Amgen | IOP, Osteoporosis | 06/23 | 06/23 | | |
| Completed | 2 | 12 | US | Romosozumab, Evenity, Alendronate, Fosamax | Northwestern University, Amgen | Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis | 06/24 | 06/24 | | |
NCT06016634: Alendronate for Osteonecrosis in Adults With Sickle Cell Disease |
|
|
| Recruiting | 2 | 24 | US | Alendronate Sodium, alendronate tablet, oral alendronate, Fosamax, Binosto | University of California, Davis, National Heart, Lung, and Blood Institute (NHLBI), Doris Duke Charitable Foundation | Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis | 12/25 | 06/26 | | |
ChiCTR1800015107: The effects of lilalucopeptide combined with alendronate on bone mineral density and serum BGP, s-ctx and BAP levels in patients with type 2 diabetes mellitus and osteoporosis. |
|
|
| Not yet recruiting | 1 | 80 | | Lilalupeptide combined with alendronate sodium therapy. ;Novorapid 30 combined with alendronate sodium. | Gansu Province Hospital of TCM; Gansu province hospital of TCM, Gansu health and family planning commission. | Type 2 diabetes | | | | |
NCT05162885: Effect of Sodium Alendronate on the Final Implant Stability. |
|
|
| Recruiting | 1 | 24 | RoW | Socket Preservation technique, Implant in socket preserved with sodium alenderonate drug | Cairo University | Anterior Labial Wall Defect | 05/21 | 10/22 | | |
NCT05771038: Assessment of Bone Quality After Socket Preservation Using Sodium Alendronate Gel Compared to Sticky Bone |
|
|
| Recruiting | 1 | 32 | RoW | socket preservation using sodium alendronate gel, socket preservation using sticky bone | Cairo University | Bone Quality Assessment, Preserved Sockets, Sodium Alendronate, Sticky Bone | 07/23 | 07/23 | | |
ChiCTR-IPR-15006922: The effect of bisphosphonates and bone density on aseptic joint loosening of the hip |
|
|
| Recruiting | 1 | 190 | | alendronate ;zoledronate | Sun yet-sen memorial hospital, Sun yet-sen university; Sun yet-sen memorial hospital，Sun yet-sen university, Sun yet-sen memorial hospital, Sun yet-sen university | aseptic joint loosening of the hip | | | | |
NCT03542695: 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy |
|
|
| Completed | 1 | 1 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Copper Cu-64-DOTA-alendronate, 64Cu-DOTA-alendronate; [64Cu]-DOTA-alendronate, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging | City of Hope Medical Center, National Cancer Institute (NCI) | Breast Carcinoma, Calcification | 05/24 | 05/24 | | |
| Not yet recruiting | 1 | 334 | | Subcutaneous injection of denosumab ;Oral alendronate sodium | Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University, foundation | refracture after vertebral augmentation | | | | |
ChiCTR2300071614: The efficacy of electroacupuncture in the treatment of thoracolumbar compression fractures in menopausal women, a prospective, two-arm, single-center randomized controlled trial protocol |
|
|
| Not yet recruiting | 1 | 124 | | The patient will be in a prone position and receive electroacupuncture treatment of BL23, BL25, BL40, BL60, GV20, KI3 and GB34. Deqi will connect the electroacupuncture device to the acupuncture and moxibustion needle with the waveform set to 2/100 Hz. After 30 minutes of treatment, electrical stimulation will be stopped, once a day for the first four weeks, and once every two days for the last eight weeks. ;1. Alendronate: 70 mg per week, fasted overnight, taken with water in the morning after waking up. 2. Salmon calcitonin: 200 International Units (IU) or 1 spray into one nostril per day, and exchange the nostril dosing use daily. 3. Calcium carbonate: 1,000 mg orally once a day. 4. Vitamin D supplements: 15 mg (600 IU) orally once a day. | Zhaoqing Medical College; Shenzhen Pingle Orthopaedic Hospital (Shenzhen Pingshan District Hospital of Traditional Chinese Medicine), Natural Science Foundation of Guangdong Province | Compression fracture | | | | |
ChiCTR1900020988: Effects of menatetrenone on the osteoblastogenic potential of circulating mesenchymal stem cells in alendronate-treated patients with glucocorticoid-induced osteoporosis |
|
|
| Recruiting | N/A | 20 | | menatetrenone, 15mg once, three times per day ;None intervention | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, self-financing | Glucocorticoid-induced osteoprosis | | | | |
ChiCTR-ICR-15006893: Osteoporosis patients after total hip replacement prosthesis research for the prevention and control of aseptic loosening |
|
|
| Recruiting | N/A | 480 | | zoledronate ;alendronate | Sun yet-sen memorial hospital, Sun yet-sen university; Sun yet-sen memorial hospital, Sun yet-sen university, Sun Set-sen Memorial hospital, Sun Yet-sen University | Osteoporosis patients after total hip replacement | | | | |
ChiCTR-IOR-16009391: Efficacy of Jian Yao Mi Gu Pian for the Treatment of Osteoporotic Low Back Pain in the Elderly: A Multi-Center Clinical Trial |
|
|
| Not yet recruiting | N/A | 250 | | Jianyao Migu Tablet+Alendronate Sodiumand VitaminD3 Tablets ;Alendronate Sodiumand Vitamin D3 Tablets | Longhua Hospital, Shanghai University of Traditional Chinese Medicine; Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Clinical Research plan of SHDC | osteoporosis | | | | |
ChiCTR-IOR-17013947: Efficacy and safety of Bushen Tiaochong Recipe combined with alendronate sodium for treating postmenopausal senile degenerative osteoporosis |
|
|
| Not yet recruiting | N/A | 200 | | alendronate sodium tablets and calcium carbonate D3 chewable tablets ;alendronate sodium tablets, calcium carbonate D3 chewable tablets and Bushen Tiaochong Recipe | Affiliated Hospital of Qinghai University; Affiliated Hospital of Qinghai University, Self-funded | postmenopausal senile degenerative osteoporosis | | | | |
ChiCTR2300067339: Effect of Bushen Zhuanggu Pills on prevent early postoperative osteolysis around the femoral prosthesis after total hip arthroplasty |
|
|
| Recruiting | N/A | 70 | | Calcium carbonate D3 + ossifying triol + Sodium alendronate + Bushen Zhuanggu Pills ;Calcium carbonate D3 + ossifying triol + Sodium alendronate | Hubei Provincial Hospital of Integrated Chinese and Western Medicine; Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, self-raised | Osteoporosis | | | | |
ChiCTR1900024376: Effect of Eucommia Yaotong Pill on Bone Mineral Density, Bone Metabolism Index and Hormone Level in Elderly Patients with Osteoporotic Low Back Pain Based on the Theory of Synergistic Treatment of Different Diseases |
|
|
| Not yet recruiting | N/A | 90 | | Basic treatment + Oral Eucommia Lower Back Pain Pill ;Basic treatment + Oral sodium alendronate ;Basic treatment (Oral Calcium + Calcitriol Capsules) | Gansu Provincial Hospital of Traditional Chinese Medicine; Gansu Provincial Hospital of Traditional Chinese Medicine, Gansu Provincial Administration of Traditional Chinese Medicine | Senile osteoporosis | | | | |
NCT03435094: Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes |
|
|
| Recruiting | N/A | 80 | Europe | Binosto 70Mg Effervescent Tablet, Fosamax 70Mg Tablet | Labatec Pharma SA | Osteoporosis, Postmenopausal | 03/22 | 12/22 | | |
ChiCTR2100052834: Evaluation and Optimization of Standardized Programs of Traditional Chinese Medicine for Prevention and Treatment of Osteoporosis |
|
|
| Recruiting | N/A | 452 | | Calcium + Vitamin D ;Calcium + Vitamin D+Fosamax ;Calcium + Vitamin D+Chinese medicine dialectical prescription ;Calcium + Vitamin D+Fosam+Chinese medicine dialectical prescription | The First Affiliated Hospital of Jinan University; The First Affiliated Hospital of Jinan University, Guangzhou Municipal Science and Technology Bureau | osteoporosis | | | | |
ChiCTR1900025266: Clinical study for multidisciplinary combined diagnosis and treatment for prevention of senile fragility fracture |
|
|
| Not yet recruiting | N/A | 80 | | Medication therapy includes active vitamin D, calcium, alendronate, etc. plus health education ;Medication therapy includes active vitamin D, calcium, alendronate, etc | The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiaotong University School of Medicine, Ninth People's Hospital, Department of Geriatrics, Science and Technology Integration Fund | Senile fragility fracture | | | | |
ChiCTR2200057669: Based on the principle of internal and external treatment and equal treatment of muscles and bones, the basic and clinical observation and study of the application of Traditional Chinese medicine intervention combined with physical factors and rehabilitation training in the treatment of sarcopenia-osteoporosis |
|
|
| Not yet recruiting | N/A | 280 | | Oral calcitol, alfacalccitol capsules and alendronate tablets ;Drug therapy combined with whole body vibration training ;Drug therapy combined with low frequency pulsed electromagnetic fields ;Drug therapy combined with whole body vibration training and low frequency pulsed electromagnetic fields ;Oral calcitol, alfacalccitol capsules and alendronate tablets ;Drug therapy combined with whole body vibration training ;Drug therapy combined with low frequency pulsed electromagnetic fields ;Drug therapy combined with whole body vibration training and low frequency pulsed electromagnetic fields ;Calcium, vitamin D and NSAIDs ;Combination of drugs and winning body sheng Gu fang ;Drug combination exercise prescription ;Medicine combined with exercise prescription and winning body sheng Bone prescription ;Oral anti-osteoporosis drugs ;Oral anti-osteoporosis drugs combined with baduanjin | Red Union Hospital affiliated to Xi 'an Jiaotong University; Red Union Hospital affiliated to Xi 'an Jiaotong University, National Natural Science Foundation of China (11872297)(31670954) | Weak muscle mass - Osteoporosis | | | | |
| Recruiting | N/A | 90 | RoW | Denosumab, Denosumab 6 month/subcutaneous, Alendronate, oral alendronate, Placebo | Shenzhen People's Hospital | Denosumab Allergy | 09/23 | 10/23 | | |
ChiCTR2000035781: 99Tc-MDP and alendronate treatments for patients with knee osteoarthritis-multicenter clinical study |
|
|
| Not yet recruiting | N/A | 252 | | 99Tc-MDP ;alendronate | Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, self depended | knee osteoarthritis | | | | |
ChiCTR2300067328: The clinical efficacy of Bushen Zhuanggu Pills on osteoporosis vertebral fractures in postmenopausal |
|
|
| Recruiting | N/A | 100 | | Calcium carbonate D3 + ossifying triol + Sodium alendronate + Bushen Zhuanggu Pills ;Calcium carbonate D3 + ossifying triol + Sodium alendronate | Hubei Provincial Hospital of Integrated Chinese and Western Medicine (Xinhua Affiliated Hospital, Hubei University of Chinese Medicine); Hubei Provincial Hospital of Integrated Chinese and Western Medicine (Xinhua Affiliated Hospital, Hubei University of Chinese Medicine), Health Commission of Hubei Province | Osteoporosis | | | | |
NCT06264401: Treatment Exercises With Core Stability and Dynamic Resistance Exercise for Postmenopausal Women With Osteoporosis |
|
|
| Completed | N/A | 60 | RoW | Alendronate, treatment exercises | Cairo University | Postmenopausal Osteoporosis | 05/24 | 06/24 | | |
NCT06392217: clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases |
|
|
| Recruiting | N/A | 500 | RoW | | Fudan University | Breast Cancer, Bone Metastases | 04/26 | 04/26 | | |
ChiCTR2200058773: Comparative study of denosumab and alendronate vitamin D3 on bone metabolism and bone mineral density after total hip arthroplasty |
|
|
| Not yet recruiting | N/A | 60 | | Denosumab ;alendronate vitamin D3 | Third Hospital of Hebei Medical University; Third Hospital of Hebei Medical University, self-funded | Osteoporosis with hip fracture, necrosis of femoral head, congenital dysplasia of hip joint | | | | |
NCT02520362: Denosumab Safety Assessment in Multiple Observational Databases |
|
|
| Active, not recruiting | N/A | 508215 | NA | denosumab, bisphosphonate | Amgen, Aarhus University Hospital, Optum, Inc., University of Alabama at Birmingham / Foundation for Advancing Science, Technology, Education and Research (FASTER) | Osteoporosis | 09/24 | 09/24 | | |
BAD, NCT04338529: Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation |
|
|
| Active, not recruiting | N/A | 92 | Europe | Binosto 70Mg Effervescent Tablet, calcium carbonate 1000 mg/d and cholecalciferol 800 IU/d | 251 Hellenic Air Force & VA General Hospital, Laikο General Hospital, Athens, 424 General Military Hospital | Postmenopausal Osteoporosis | 09/24 | 11/24 | | |
ChiCTR2200061781: Therapeutic effect of combined aldosterone receptor antagonist on postmenopausal osteoporosis |
|
|
| Not yet recruiting | N/A | 122 | | Calcium intake was 1200mg(elemental calcium)/ day, calcitriol 0.25ug/ day, alendronate 70mg/ week, spironolactone 40mg/ day (orally divided twice). Patients with poor blood pressure control were combined with CCB antihypertensive drugs to control blood pressure ;Calcium intake was 1200mg(elemental calcium)/ day, calcitriol 0.25ug/ day, alendronate 70mg/ week and CCB antihypertensive drugs were given to control blood pressure | Beijing Luhe Hospital, Capital Medical University; Beijing Luhe Hospital, Capital Medical University, The present study received the support from Capital Health development Scientific Research project[2022-4-7101] | postmenopausal osteoporosis | | | | |
ChiCTR2400085875: The Effects of Zhuanggu Qiangji Decoction on muscle strength, bone metabolism and quality of life of postmenopausal osteoporosis patients |
|
|
| Not yet recruiting | N/A | 66 | | Basic treatment+ Zhuanggu Qiangji Decoction (10g/time, 2 times/day), 12 weeks; Basic treatment+ Alendronate Sodium Tablet (1 tablet/time, 1 dose/week), 12 weeks. | The Third Affiliated Hospital of Guangzhou University of Chinese Medicine; The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Self-funded | postmenopausal osteoporosis | | | | |
NCT03692143: Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP |
|
|
| Active, not recruiting | N/A | 90 | NA | Teriparatide, PVP, Alendronate | Nanfang Hospital of Southern Medical University | Osteoporosis, Postmenopausal, Vertebral Fracture, Quality of Life | 03/25 | 12/30 | | |
EURODEC, NCT05575167: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) |
|
|
| Recruiting | N/A | 125 | Europe | Zoledronate or Alendronate, Calcium and vitamin D supplementation | 424 General Military Hospital | Osteoporosis, Postmenopausal | 11/26 | 11/26 | | |
ChiCTR2300078907: The effect of Desucumab on muscle mass and strength in postmenopausal women with osteoporosis: a randomized, parallel controlled drug study |
|
|
| Recruiting | N/A | 120 | | Denosumab, Amgen Company, registered trade name of Prolide in Chinese Mainland, injection, 60mg/piece, 60mg q6m SC; Basic drugs (both the test group and the control group): calcium carbonate D3 tablet, Wyeth Pharmaceutical Co., Ltd., registered trade name of calci D in Chinese Mainland, tablet, containing 1.5g calcium carbonate (equivalent to 600mg calcium), VitD3 125IU, 1 tablet qd po.; Alendronate Sodium Tablets, MSD (China) Co., Ltd., registered in Chinese Mainland under the trade name of Fushanmei, tablet, containing 70mg of Alendronate Sodium Tablets, 70mg qw po.Basic drugs (both the test group and the control group): calcium carbonate D3 tablet, Wyeth Pharmaceutical Co., Ltd., registered trade name of calci D in Chinese Mainland, tablet, containing 1.5g calcium carbonate (equivalent to 600mg calcium), VitD3 125IU, 1 tablet qd po. | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Discipline - First Class Excellence - Orthopedics | Osteoporosis and sarcopenia | | | | |
ChiCTR2400082213: Study on the Influencing Factors of the Effect of Sodium Alendronate Combined with Calcium Carbonate D3 in Improving Bone Density in Maintenance Hemodialysis Patients with Renal Osteodystrophy. |
|
|
| Not yet recruiting | N/A | 120 | | sodium alendronate and calcium carbonate D3; calcium carbonate D3 | nanchong psychosomatic hospital; nanchong psychosomatic hospital, Self-funding by the Nanchong Municipal Science and Technology Bureau and affiliated units. | Maintenance hemodialysis-associated osteoporosis. | | | | |
| Active, not recruiting | N/A | 80 | Europe | Musculoskeletal health package | The Christie NHS Foundation Trust | Gynecologic Cancer, Radiotherapy Side Effect, Fracture | 08/25 | 08/25 | | |
ChiCTR2000029392: The Effect of Postoperative Use of Bisphosphates on Rotator Cuff Repair |
|
|
| Recruiting | N/A | 86 | | bisphosphates （Alendronate） ;no bisphosphates （blank control） | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, National Natural Science Foundation of China | rotater cuff tear | | | | |
ChiCTR2400085924: Bone protective effect of alendronate sodium in patients with stage CKD1-3 treated with glucocorticoids: a multicenter randomized controlled study |
|
|
| Not yet recruiting | N/A | 200 | | Alendronate sodium + calcium carbonate D3+ calcitriol capsules; calcium carbonate D3+ calcitriol capsules | Xijing Hospital affiliated to Air Force Medical University; Xijing Hospital affiliated to Air Force Medical University, self-financing | CKD1-3 stage | | | | |
ChiCTR2400086604: Alendronate sodium in the treatment of mineral and bone metabolic abnormalities in peritoneal dialysis patients: a multicenter randomized controlled study |
|
|
| Not yet recruiting | N/A | 200 | | Alendronate sodium + calcitriol capsules; calcitriol capsules | Xijing Hospital affiliated to Air Force Medical University; Xijing Hospital affiliated to Air Force Medical University, self-financing | CKD-MBD | | | | |
| Active, not recruiting | N/A | 284 | | | NHMRC, NHMRC | Fracture neck of femur | | | | |
| Recruiting | N/A | 44 | | | Bone Research Group, Garvan Institute of Medical Research, Bone Research Group
Garvan Institute Medical Research | Osteoporosis, Immune system | | | | |
ACTRN12621001208897: Comparative Persistence With Prolia and Weekly Alendronate in 5 Asia-Pacific countries: a Prospective Observational Study. |
|
|
| Recruiting | N/A | 770 | | | Amgen Inc., Amgen Inc. | Osteoporosis | | | | |
NCT04861142: Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy |
|
|
| Recruiting | N/A | 350 | Europe | Anti-osteoporotic medication( alendronate or denosumab) | University General Hospital of Heraklion | Osteoporosis | 05/24 | 10/24 | | |
